MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its ...
The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.
SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...
Other updates came as no surprise. The company still expects revenue growth of up to 10% in 2026, and reiterated that it ...
12d
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback